文献速递银屑病与炎症性皮肤病

Corrona银屑病登记队列:疾病负担、合并症与治疗使用特征

Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
PubMed 文献 · J Am Acad Dermatol · 2017-10-16

该横断面研究基于Corrona银屑病登记系统,纳入1942例在入组时或过去12个月内启动或换用系统治疗的患者,描述其人口学、临床结局、合并症及治疗史。结果显示平均病程15.6年,40%合并银屑病关节炎,66%体表面积>3%,49%研究者总体评估为中重度;治疗以TNF抑制剂、IL-17A抑制剂等生物制剂为主。

要点

  • Corrona登记队列反映真实世界银屑病患者病程长、合并症多。
  • 40%患者合并银屑病关节炎,49%为中重度IGA。
  • 治疗分布以TNF抑制剂、IL-17A抑制剂和IL-12/23抑制剂为主。

核心结论

  • 该疾病登记队列代表了暴露于多种疗法、病程长且合并症多的银屑病患者人群,可用于比较不同疗法的安全性和有效性。

研究设计与样本

  • 横断面研究,纳入Corrona银屑病登记中在入组时或过去12个月内启动或换用系统治疗的1942例患者。

主要发现

  • 总体平均病程为15.6年,40%患者合并银屑病关节炎诊断。
  • 约66%患者体表面积受累>3%,49%患者研究者总体评估为中度或重度。

关键数值与推荐

  • 平均病程15.6年;40%合并银屑病关节炎;66%体表面积>3%;49%IGA为中重度。

临床怎么用

  • 该登记数据可用于描述真实世界银屑病患者的疾病负担、合并症谱及系统治疗使用模式。

局限性

  • 选择偏倚和通道偏倚可能导致潜在混杂,需在建模分析中处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is an immunodysregulatory inflammatory disease associated with comorbidities affecting quality of life. With the advent of new treatments, there is growing need to assess the long-term safety and efficacy of treatments in a real-world setting. OBJECTIVE: The objective of the Corrona Psoriasis Registry is to study the comparative safety and efficacy of Food and Drug Administration-approved biologic treatments. METHODS: A cross-sectional study of patients enrolled in the registry, who initiated or switched to a systemic therapy at enrollment or previous 12 months. Descriptive characteristics (demographics, clinical and patient-reported outcomes, comorbidities, and treatment history) were examined at registry enrollment. RESULTS: As of October 1, 2016, there were 1942 patients enrolled in the registry: 23% on apremilast, 4% on other nonbiologic systemic medications, 25% on interleukin (IL) 17A inhibitors, 22% on an IL-12/23 inhibitor, and 26% on tumor necrosis factor inhibitors. Overall, mean disease duration was 15.6 years, and 40% had a concurrent psoriatic arthritis diagnosis. About 66% had >3% body surface area involvement and 49% had a moderate or severe Investigator Global Assessment. LIMITATIONS: Selection and channeling bias can result in potential confounding that needs to be addressed in modeled analyses. CONCLUSION: This disease-based registry cohort represents a population exposed to multiple therapies, long disease duration, and multiple comorbidities and can be used to examine comparative safety and efficacy of various therapies.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2017. PMID: 29051036. doi:10.1016/j.jaad.2017.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。